Dark
Streaming/Mobile
OldĀ Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:33:44 EDT Sat 27 Apr 2024
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
News for U:RVVTF from 2023-04-27 to 2024-04-26 - 24 items
News Releases
In The News
Other
CA
US
Date
Sym
Price
Type
Headline
2024-04-23 07:00
U
U:RVVTF
News Release
200
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
2024-04-18 07:00
U
U:RVVTF
News Release
200
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
2024-04-02 07:30
U
U:RVVTF
News Release
200
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
2024-03-27 09:09
U
U:RVVTF
News Release
200
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
2024-03-19 07:00
U
U:RVVTF
News Release
200
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
2024-03-12 07:00
U
U:RVVTF
News Release
200
Revive Therapeutics Provides Corporate Update
2024-02-26 16:05
U
U:RVVTF
News Release
200
Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110
2024-02-01 07:30
U
U:RVVTF
News Release
200
Revive Therapeutics Explores the Use of Bucillamine for Long COVID
2024-01-31 17:06
U
U:RVVTF
News Release
200
Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500
2024-01-24 17:56
U
U:RVVTF
News Release
200
Revive Therapeutics Ltd. Announces Offering of Up to $3 Million
2024-01-16 07:00
U
U:RVVTF
News Release
200
Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada
2024-01-10 07:00
U
U:RVVTF
News Release
200
Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine
2023-12-20 12:54
U
U:RVVTF
News Release
200
Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
2023-12-18 07:00
U
U:RVVTF
News Release
200
Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine
2023-11-21 07:30
U
U:RVVTF
News Release
200
Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
2023-11-06 07:45
U
U:RVVTF
News Release
200
Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test
2023-10-17 07:00
U
U:RVVTF
News Release
200
Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure
2023-10-11 08:50
U
U:RVVTF
News Release
200
Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
2023-08-22 06:30
U
U:RVVTF
News Release
200
Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development
2023-07-28 07:00
U
U:RVVTF
News Release
200
Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents
2023-07-06 06:30
U
U:RVVTF
News Release
200
Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
2023-05-30 07:30
U
U:RVVTF
News Release
200
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
2023-05-12 07:00
U
U:RVVTF
News Release
200
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
2023-05-02 06:00
U
U:RVVTF
News Release
200
Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19